Compare LYEL & CNOBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYEL | CNOBP |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.1M | N/A |
| IPO Year | 2021 | 1995 |
| Metric | LYEL | CNOBP |
|---|---|---|
| Price | $11.02 | $25.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.60 | N/A |
| AVG Volume (30 Days) | ★ 88.6K | 3.4K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.51 |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8,712.13 | N/A |
| P/E Ratio | ★ N/A | $16.81 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.46 | $23.80 |
| 52 Week High | $45.00 | $25.51 |
| Indicator | LYEL | CNOBP |
|---|---|---|
| Relative Strength Index (RSI) | 27.52 | 58.25 |
| Support Level | N/A | $24.87 |
| Resistance Level | $15.38 | $25.48 |
| Average True Range (ATR) | 0.77 | 0.10 |
| MACD | -0.39 | 0.00 |
| Stochastic Oscillator | 2.56 | 61.86 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.